ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.884,75
-0,57%
S&P 500
5.930,85
1,09%
Dow Jones
42.840,26
1,18%
Euro vs US Dollar
1,043
0,00%
Bitcoin
97.094,87
-0,12%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ

  6. Lipella Pharmaceuticals Inc (LIPO) Börsenkurse

Lipella Pharmaceuticals Inc

Lipella Pharmaceuticals Inc (LIPO)

NASDAQ
2,61
0,04
(1,56%)
Geschlossen 22 Dezember 10:00PM
Verzögert um 15 Minuten
2,66
0,05
(1,92%)
Nach Börsenschluss: 1:51AM
Verzögert um 15 Minuten

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Wichtige Statistiken und Details

Current Price
2,66
Gebot
2,65
Fragen
2,73
Volumen
58.914
2,57 Tagesbereich 2,76
2,21 52-Wochen-Bereich 12,00
Marktkapitalisierung
3,216M
Handelsende
2,57
Handelsbeginn
2,60
Letzte Trade
250
@
2.66
(formt)
Letzter Handelszeitpunkt
Finanzvolumen
US$ 157.190
VWAP
2,6681
Durchschnittliches Volumen (3 Mio.)
881.067
Ausgegebene Aktien
1.208.919
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-0,69
Gewinn pro Aktie (EPS)
-3,82
Erlöse
450k
Nettogewinn
-4,62M

Über Lipella Pharmaceuticals Inc

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinic... Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is based in Pittsburgh, Pennsylvania. Mehr anzeigen

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Website
www.lipella.com
Hauptsitz
Wilmington, Delaware, USA
Gegründet
-
Lipella Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LIPO. The last closing price for Lipella Pharmaceuticals was US$2,57. Over the last year, Lipella Pharmaceuticals shares have traded in a share price range of US$ 2,21 to US$ 12,00.

Lipella Pharmaceuticals currently has 1.208.919 shares in issue. The market capitalisation of Lipella Pharmaceuticals is US$3,11 million. Lipella Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.69.

LIPO Neueste Nachrichten

Weitere Nachrichten

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

20 Dezember 2024
Edgar (US Regulatory)

Form 8-K - Current report

20 Dezember 2024
Edgar (US Regulatory)

Form 8-K - Current report

10 Dezember 2024
Edgar (US Regulatory)

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

06 Dezember 2024
Edgar (US Regulatory)

Form 8-K - Current report

06 Dezember 2024
Edgar (US Regulatory)

Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus

PITTSBURGH, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotechnology company dedicated to addressing serious diseases with significant unmet...

03 Dezember 2024
GlobeNewswire Inc.

Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group

PITTSBURGH, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on innovative therapies for...

21 November 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

14 November 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

14 November 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

14 November 2024
Edgar (US Regulatory)
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10.083.10077519382.582.792.53356052.63421195CS
40.249.91735537192.423.562.421631262.95779665CS
12-1.1944-30.98796180993.85444.1162.218810673.39136457CS
26-2.42-47.63779527565.08122.2122168376.13945278CS
52-5.34-66.758122.2111457596.1456873CS
156-53.5-95.263532763556.1661.762.2179124610.18968827CS
260-53.5-95.263532763556.1661.762.2179124610.18968827CS

LIPO - Frequently Asked Questions (FAQ)

What is the current Lipella Pharmaceuticals share price?
The current share price of Lipella Pharmaceuticals is US$ 2,66
How many Lipella Pharmaceuticals shares are in issue?
Lipella Pharmaceuticals has 1.208.919 shares in issue
What is the market cap of Lipella Pharmaceuticals?
The market capitalisation of Lipella Pharmaceuticals is USD 3,11M
What is the 1 year trading range for Lipella Pharmaceuticals share price?
Lipella Pharmaceuticals has traded in the range of US$ 2,21 to US$ 12,00 during the past year
What is the PE ratio of Lipella Pharmaceuticals?
The price to earnings ratio of Lipella Pharmaceuticals is -0,69
What is the cash to sales ratio of Lipella Pharmaceuticals?
The cash to sales ratio of Lipella Pharmaceuticals is 7,07
What is the reporting currency for Lipella Pharmaceuticals?
Lipella Pharmaceuticals reports financial results in USD
What is the latest annual turnover for Lipella Pharmaceuticals?
The latest annual turnover of Lipella Pharmaceuticals is USD 450k
What is the latest annual profit for Lipella Pharmaceuticals?
The latest annual profit of Lipella Pharmaceuticals is USD -4,62M
What is the registered address of Lipella Pharmaceuticals?
The registered address for Lipella Pharmaceuticals is 108 WEST 13TH STREET, WILMINGTON, DELAWARE, 19801
What is the Lipella Pharmaceuticals website address?
The website address for Lipella Pharmaceuticals is www.lipella.com
Which industry sector does Lipella Pharmaceuticals operate in?
Lipella Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Beweger

Alle Anzeigen
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
MYSZMy Size Inc
US$ 4,2001
(211,12%)
121,03M
NVNINVNI Group Ltd
US$ 8,26
(209,36%)
78,06M
TPICTPI Composites Inc
US$ 2,45
(100,82%)
34M
ICGIntchains Group Ltd
US$ 8,77
(88,60%)
527,94k
HSDTHelius Medical Technologies Inc
US$ 0,884851
(84,34%)
121,95M
CYNCYNGN Inc
US$ 0,4603
(-71,41%)
27,91M
MTEMMolecular Templates Inc
US$ 0,1502
(-57,09%)
8,75M
PRFXPainReform Ltd
US$ 5,15
(-53,85%)
2,94M
GALTGalectin Therapeutics Inc
US$ 1,03
(-48,50%)
9,27M
BCABBioAtla Inc
US$ 0,6923
(-41,82%)
6,25M
EDBLEdible Garden AG Inc
US$ 0,24
(65,06%)
354,33M
NVDANVIDIA Corporation
US$ 134,70
(3,08%)
310,19M
APTOAptose Biosciences Inc
US$ 0,28
(64,51%)
306,25M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0,606999
(6,49%)
293,22M
PLTRPalantir Technologies Inc
US$ 80,55
(8,54%)
281,23M

Foren

Foren anzeigen
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

NASDAQ
LIPO
Lipella Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten